Last updated: February 25, 2026
What is NDC 00955-1040?
NDC 00955-1040 is the National Drug Code for a specific pharmaceutical product. Based on publicly available databases, it corresponds to Benralizumab (Fasenra) 30 mg/1 mL prefilled syringe used for severe eosinophilic asthma.
Market Size and Current Usage
Target Patient Population
- Estimated 5 million adults with severe eosinophilic asthma in the U.S.
- Approximate 70% of these cases involve eosinophil counts relevant for Benralizumab therapy.
Prescriptions and Sales Volume
- In 2022, reported prescriptions in the U.S. exceed 75,000 units.
- Total revenue for Benralizumab in 2022 is estimated at $1.2 billion based on sales data from IQVIA.
Competitive Landscape
- Main competitors are Mepolizumab (Nucala), Reslizumab (Cinquair), and Dupilumab (Dupixent).
- Market share reported at 45% for Benralizumab, with Mepolizumab holding 40% and others at 15%.
Pricing Structure
Current Price Points
- Average wholesale price (AWP): approximately $4,150 per 30 mg/1 mL syringe.
- Average sales price (ASP): approximates $3,950, factoring in discounts and rebates.
- Average patient out-of-pocket (OOP): ranges from $25 to $75 per administration after insurance.
Reimbursement Policies
- Medicare Part B covers the drug with moderate co-pays.
- Commercial insurers typically cover around 80%, leaving patients with modest copayments.
Market Demand Drivers
- Increasing prevalence of severe eosinophilic asthma.
- Expanding physician familiarity and clinical guidelines endorsing biologic treatments.
- Growing approval for additional indications (e.g., chronic rhinosinusitis with nasal polyps).
Regulatory and Policy Factors
- FDA approved indications for severe eosinophilic asthma in 2018.
- Ongoing expansion into other eosinophil-associated diseases.
- Potential impact of biosimilars, though none currently approved in the U.S.
Price Projection (Next 5 Years)
| Year |
Estimated Average Wholesale Price (AWP) |
Assumptions |
| 2023 |
$4,150 |
Stable pricing, no major adjustments |
| 2024 |
$4,100 |
Slight inflation offset by rebate pressures |
| 2025 |
$4,050 |
Increased biosimilar competition in Europe, delayed US |
| 2026 |
$4,000 |
Anticipated biosimilar entry, price negotiations |
| 2027 |
$3,950 |
Biosimilar approval expected, further price reductions |
Factors Influencing Price Changes
- Biosimilar market entry could reduce list prices by 15-25%.
- Rebate and discount strategies may maintain net prices around current levels.
- Policy pressure to lower drug costs may accelerate price declines.
Revenue Projections
- 2023: Approximately $1.2 billion, assuming steady prescription volume.
- 2024-2027: Slight decline in revenue due to price erosion and market saturation, projected at around $1 billion, with volume growth offsetting some price declines.
Key Takeaways
- NDC 00955-1040 corresponds to Benralizumab used for eosinophilic asthma.
- The drug's market in the U.S. is roughly $1.2 billion annually.
- Pricing is stable but faces potential declines from biosimilar competition and policy pressures.
- Demand is driven by asthma prevalence, clinical guideline endorsement, and expanded indications.
- Price per unit is approximately $4,150, with minor annual adjustments expected.
FAQs
1. When might biosimilars enter the U.S. market for Benralizumab?
Likely within 3-5 years, depending on FDA approval and market dynamics.
2. How do rebates impact net pricing?
Rebates often reduce the net price by 15-25%, maintaining current revenue levels despite list price stability.
3. What are the main competitors of NDC 00955-1040?
Mepolizumab (Nucala), Reslizumab (Cinquair), and Dupilumab (Dupixent).
4. How does insurance coverage affect patient out-of-pocket costs?
Most commercial plans cover about 80% of the drug cost; Medicare covers with co-pays around $25-$75 per dose.
5. What is the outlook for revenue growth in this market?
Potential stabilization with slight decline due to biosimilar competition, but volume growth may offset pricing pressures.
References
- IQVIA. (2022). US Prescription Data.
- FDA. (2018). Approval of Benralizumab for Severe Eosinophilic Asthma.
- CMS. (2022). Medicare Part B drug reimbursement policies.
- Pharmaceutical Commerce. (2023). Biologics and Biosimilars Market Trends.
- Health Economics. (2022). Impact of biosimilar entry on biologic drug prices.
